Advertisement

Current Dermatology Reports

, Volume 5, Issue 1, pp 1–4 | Cite as

Japan Pharmacogenomics Data Science Consortium Database and Its Application for Drug Safety Analyses

  • Koji Suematsu
Cutaneous Drug Reactions (J. Brieva, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Cutaneous Drug Reactions

Abstract

Severe adverse drug reactions (ADRs) are significantly influenced by the genetic background of an individual, and pharmacogenomics (PGx) is strongly expected to reveal the cause of severe ADRs. Genome-wide association studies (GWASs) for severe ADRs have been conducted worldwide, and a genomic database of representative samples of the ethnic population can be used as controls for GWAS for severe ADRs. Six Japanese pharmaceutical companies, Astellas, Daiichi Sankyo, Mitsubishi Tanabe, Otsuka, Taisho, and Takeda, therefore established the Japan Pharmacogenomics Data Science Consortium (JPDSC) and built a Japanese genomic database in 2009. This database promotes the application of PGx in drug development by each member company and PGx researches for expanding Japanese drug safety information at the genomic level.

Keyword

Pharmacogenomics GWAS Drug safety 

Notes

Compliance with Ethical Standards

Conflict of Interest

Koji Suematsu declares that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Nakamura Y. DNA variations in human and medical genetics: 25 years of my experience. J Hum Genet. 2009;54:1–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Xu CF, Lewis KF, Yeo AJ, et al. Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J. 2004;4:374–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Nelson MR, Bacanu SA, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 2009;9:23–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol. 2012;30:1117–24.CrossRefPubMedGoogle Scholar
  6. 6.•
    Kamitsuji S, Matsuda T, Nishimura K, et al. Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies. J Hum Genet. 2015;60:319–26. The study evaluates the database in the various aspects of genetics and shows it will be useful as control data for conducting PGx studies.CrossRefPubMedGoogle Scholar
  7. 7.••
    Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13:60–9. The study revealed that the SNPs on chromosome 6 including rs9263726 in PSORS1C1 in absolute linkage disequilibrium with HLA-B*5801 are in strong association with allopurinol-induced SJS/TEN in Japanese.Google Scholar
  8. 8.••
    Kaniwa N, Sugiyama E, Saito Y, et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14:1821–31. The study suggests that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers respectively for zonisamide- and phenobarbital-induced SJS/TEN in Japanese.Google Scholar
  9. 9.••
    Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312:525–34. The study identified CYP2C9*3 known to reduce drug clearance as an important genetic factor associated with phenytoin-induced severe cutaneous adverse reactions.Google Scholar
  10. 10.••
    Maekawa K, Nakamura R, Kaniwa N, et al. Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese. Pharmacogenomics. 2015;16:1689–99. The study revealed that the three SNPs, rs1150738, rs3869066 and rs259945, are the useful biomarkers in absolute linkage disequilibrium with HLA-A*31:01 , a risk factor for carbamazepine related SJS/TEN in Japanese.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Taisho Pharmaceutical Co., Ltd.Toshima-kuJapan

Personalised recommendations